XTL Biopharmaceuticals
Treatments for Autoimmune Diseases
Company Overview
Snapshot
Founded in March 1993, XTL Biopharmaceuticals operates with 1–10 employees. The company has raised a total of $30.04 million across 6 funding rounds from 8 investors. In January 2026, XTL Biopharmaceuticals acquired 85% of NeuroNOS, a subsidiary of Beyond Air, marking its entry into the autism market.
Business overview
XTL Biopharmaceuticals is a public company focused on the acquisition and development of late-stage pharmaceutical product candidates to address unmet clinical needs. The company's pipeline includes hCDR1 peptide for systemic lupus erythematosus (SLE), recombinant erythropoietin for advanced-stage multiple myeloma patients, and SAM-101 for psychotic diseases, particularly schizophrenia. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Drugs Discovery & Development, XTL Biopharmaceuticals serves the pharmaceutical industry with its biological-based solutions.
Strategic signal
In May 2026, XTL Biopharmaceuticals received a Staff Delist Determination from Nasdaq, indicating significant compliance challenges with listing requirements. This development signals potential instability and raises concerns for investors regarding the company's continued public trading status and its ability to access capital markets, despite recent strategic acquisitions.
Log in to access full profile ›Company Intelligence Q&A
- What was the most recent acquisition made by XTL Biopharmaceuticals?
- In June 2026, XTL Biopharmaceuticals completed the acquisition of Psyga Bio Ltd, establishing a psychedelic biotechnology platform with an advanced clinical pipeline, licensed GMP manufacturing, and proprietary psilocybin technologies.
- What was the outcome of the Nasdaq notification regarding minimum bid price deficiency in May 2026?
- In May 2026, XTL Biopharmaceuticals announced the receipt of a Staff Delist Determination from Nasdaq and stated plans to request a hearing to address the deficiency.
- What strategic move did XTL Biopharmaceuticals make in January 2026?
- In January 2026, XTL Biopharmaceuticals acquired 85% of NeuroNOS, a subsidiary of Beyond Air, marking its entry into the autism market with a focus on Nobel Prize-winning scientific leadership.
- What was the most recent funding activity for XTL Biopharmaceuticals?
- In August 2024, XTL Biopharmaceuticals completed a private placement of $1.5 million in conjunction with the acquisition of The Social Proxy.
- What was the purpose of the acquisition of The Social Proxy by XTL Biopharmaceuticals?
- In August 2024, XTL Biopharmaceuticals completed the acquisition of The Social Proxy, following a definitive agreement entered in June 2024. The acquisition was accompanied by a private placement of $1.5 million.